Evidence map›Paper›PMID 28695160›Full record

ArticleTechnology2017

Recent advances in nonbiofouling PDMS surface modification strategies applicable to microfluidic technology.

Aslihan Gokaltun, Martin L Yarmush, Ayse Asatekin, O Berk Usta

Abstract read
In one paragraph

Article in Technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 171 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Aslihan GokaltunCenter for Engineering in Medicine at Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, 51 Blossom St., Boston, MA 02114, USA.
Martin L YarmushCenter for Engineering in Medicine at Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, 51 Blossom St., Boston, MA 02114, USA.
Ayse AsatekinDepartment of Chemical and Biological Engineering, Tufts University, 4 Colby Street, Medford, MA 02474, USA.
O Berk UstaCenter for Engineering in Medicine at Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, 51 Blossom St., Boston, MA 02114, USA.
Tufts University · USRutgers, The State University of New Jersey · USShriners Hospitals for Children - Erie · US

Funding

Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
Real Time Elucidation of Drug-Drug Interactions via Dual Reporter Cell Technology and Microfabricated ArraysR01EB023812 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET, YARMUSH, MARTIN L · 2016 to 2019
$1.8M
Novel Microfluidic Platforms for Actively Controlled in-vitro Liver ZonationR21EB020192 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI USTA, OSMAN BERK · 2015 to 2016
$479k
NIBIB NIH HHS P41 EB002503NIBIB NIH HHS R01 EB023812NIBIB NIH HHS R21 EB020192
6 · The paper itself

Abstract

In the last decade microfabrication processes including rapid prototyping techniques have advanced rapidly and achieved a fairly mature stage. These advances have encouraged and enabled the use of microfluidic devices by a wider range of users with applications in biological separations and cell and organoid cultures. Accordingly, a significant current challenge in the field is controlling biomolecular interactions at interfaces and the development of novel biomaterials to satisfy the unique needs of the biomedical applications. Poly(dimethylsiloxane) (PDMS) is one of the most widely used materials in the fabrication of microfluidic devices. The popularity of this material is the result of its low cost, simple fabrication allowing rapid prototyping, high optical transparency, and gas permeability. However, a major drawback of PDMS is its hydrophobicity and fast hydrophobic recovery after surface hydrophilization. This results in significant nonspecific adsorption of proteins as well as small hydrophobic molecules such as therapeutic drugs limiting the utility of PDMS in biomedical microfluidic circuitry. Accordingly, here, we focus on recent advances in surface molecular treatments to prevent fouling of PDMS surfaces towards improving its utility and expanding its use cases in biomedical applications.

Indexed as

MicrochannelsMicrofluidicsNonspecific Protein AdsorptionPDMSSmall Molecule AbsorptionSurface ModificationTissue-on-Chips

Identifiers

PMID28695160
PMCPMC5501164
OpenAlexW2587183677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.